Skip to main content Accessibility help

Keeping up with the therapeutic advances in schizophrenia: a review of novel and emerging pharmacological entities

  • Amanda Krogmann (a1), Luisa Peters (a1), Laura von Hardenberg (a1), Katja Bödeker (a1), Viktor B. Nöhles (a1) and Christoph U. Correll (a1) (a2) (a3)...


Schizophrenia remains one of the most severe medical diseases. Current dopamine modulating first-generation and second-generation antipsychotics target mainly positive symptoms, but not/inadequately negative and cognitive symptoms. Additional challenges include non-adherence and adverse effects, especially cardiometabolic dysregulation. This review evaluates new/emerging pharmacological treatments for schizophrenia. Therapies targeting total symptoms include cannabidiol, D3 antagonist/5-HT1A partial agonist F17464, lumateperone (ITI-007), phosphodiesterase 10A (PDE10A) inhibitors MK-8189 and TAK-063, sodium nitroprusside, and trace amine-associated receptor-1 (TAAR1) agonist RO5263397 and SEP-363856. Treatments targeting negative symptoms include the PDE10A inhibitor LuAF-11167, 5-HT2A inverse agonist pimavanserin, sigma-2/5-HT2A antagonist roluperidone (MIN-101), and d-amino acid oxidase (DAAO) inhibitor TAK-831. Agents targeting primarily cognitive dysfunction are the glycine transporter-1 inhibitor BI-425809 and cannabidiol. Therapies targeting residual positive symptoms/treatment-resistant schizophrenia include pimavanserin, dopamine D1/D2 antagonist LuAF-35700, and DAAO inhibitor sodium benzoate. Two new long-acting injectable antipsychotic formulations, Aripiprazole Lauroxil NanoCrystal® and the first subcutaneous injectable LAI Perseris (RBP-7000), were recently approved by U.S. Food and Drug Administration, and positive results were announced for Risperidone ISM®, each achieving therapeutic levels within 24 hours, without need for initial oral cotreatment/loading injection-strategies. Paliperidone palmitate 6-monthly intramuscularly injectable and Risperidone subcutaneously injectable TV46000 are currently under investigation. Finally, the samidorphan+olanzapine combination targets reduced weight gain liability, while maintaining olanzapine’s efficacy. Most of these trial programs are still ongoing or have yielded mixed or even negative results. Thus, additional mechanisms of action and agents require study to improve schizophrenia outcomes for total/positive symptoms with reduced adverse effects, but also cognitive symptoms, negative symptoms, and treatment resistance, the areas of greatest need in schizophrenia currently.


Corresponding author

*Address correspondence to: Christoph U. Correll, MD, The Zucker Hillside Hospital, Psychiatry Research, 75-59 263rd Street, Glen Oaks, New York 11004, USA. (Email:


Hide All

The authors contributed equally to this work.

This activity is supported by an unrestricted educational grant from Indivior.



Hide All
1. Kahn, RS, Sommer, IE, Murray, RM, et al. Schizophrenia. Nat Rev Dis Primer. 2015; 1: 15069. doi: 10.1038/nrdp.2015.69
2. DiBonaventura, M, Gabriel, S, Dupclay, L, et al.. A patient perspective of the impact of medication side effects on adherence: results of a cross-sectional nationwide survey of patients with schizophrenia. BMC Psychiatry. 2012; 12(1): 20. doi: 10.1186/1471-244X-12-20
3. National Institute for Health and Care Excellence (NICE). Psychosis and schizophrenia in adults: prevention and management.. Nice Guidelines. Accessed June 27, 2019.
4. Kane, JM, Correll, CU. Pharmacologic treatment of schizophrenia. Dialogues Clin Neurosci. 2010; 12(3): 345357.
5. Leucht, S, Leucht, C, Huhn, M, et al. Sixty years of placebo-controlled antipsychotic drug trials in acute schizophrenia: systematic review, Bayesian meta-analysis, and meta-regression of efficacy predictors. Am J Psychiatry. 2017; 174(10): 927942. doi: 10.1176/appi.ajp.2017.16121358
6. Leucht, S, Tardy, M, Komossa, K, et al. Antipsychotic drugs versus placebo for relapse prevention in schizophrenia: a systematic review and meta-analysis. Lancet Lond Engl. 2012; 379(9831): 20632071. doi: 10.1016/S0140-6736(12)60239-6
7. Kishimoto, T, Agarwal, V, Kishi, T, et al. Relapse prevention in schizophrenia: a systematic review and meta-analysis of second-generation antipsychotics versus first-generation antipsychotics. Mol Psychiatry. 2013; 18(1): 5366. doi: 10.1038/mp.2011.143
8. Correll, CU, Rubio, JM, Kane, JM. What is the risk-benefit ratio of long-term antipsychotic treatment in people with schizophrenia? World Psychiatry. 2018; 17(2): 149160. doi: 10.1002/wps.20516
9. Kishimoto, T, Hagi, K, Nitta, M, et al. Long-term effectiveness of oral second-generation antipsychotics in patients with schizophrenia and related disorders: a systematic review and meta-analysis of direct head-to-head comparisons. World Psychiatry. 2019; 18(2): 208224.
10. Lieberman, JA. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia: efficacy, safety and cost outcomes of CATIE and other trials. J Clin Psychiatry. 2007; 68(2): e04. doi: 10.4088/JCP.0207e04
11. Lim, SS, Vos, T, Flaxman, AD, et al. A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012; 380(9859): 22242260. doi: 10.1016/S0140-6736(12)61766-8
12. Murray, CJL, Vos, T, Lozano, R, et al. Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet Lond Engl. 2012; 380(9859): 21972223. doi: 10.1016/S0140-6736(12)61689-4
13. Vos, T, Flaxman, AD, Naghavi, M, et al. Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet Lond Engl. 2012; 380(9859): 21632196. doi: 10.1016/S0140-6736(12)61729-2
14. Salomon, JA, Vos, T, Hogan, DR, et al. Common values in assessing health outcomes from disease and injury: disability weights measurement study for the Global Burden of Disease Study 2010. Lancet Lond Engl. 2012; 380(9859): 21292143. doi: 10.1016/S0140-6736(12)61680-8
15. Correll, CU. The prevalence of negative symptoms in schizophrenia and their impact on patient functioning and course of illness. J Clin Psychiatry. 2013; 74(2): e04.
16. Insel, TR. Rethinking schizophrenia. Nature. 2010; 468(7321): 187193. doi: 10.1038/nature09552
17. McGorry, PD, Yung, AR, Bechdolf, A, et al. Back to the future: predicting and reshaping the course of psychotic disorder. Arch Gen Psychiatry. 2008; 65(1): 2527. doi: 10.1001/archgenpsychiatry.2007.9
18. Mosolov, SN, Potapov, AV, Ushakov, UV. Remission in schizophrenia: results of cross-sectional with 6-month follow-up period and 1-year observational therapeutic studies in an outpatient population. Ann Gen Psychiatry. 2012; 11: 1. doi: 10.1186/1744-859X-11-1
19. Millan, MJ, Fone, K, Steckler, T, et al. Negative symptoms of schizophrenia: clinical characteristics, pathophysiological substrates, experimental models and prospects for improved treatment. Eur Neuropsychopharmacol. 2014; 24(5): 645692. doi: 10.1016/j.euroneuro.2014.03.008
20. Carbon, M, Correll, CU. Thinking and acting beyond the positive: the role of the cognitive and negative symptoms in schizophrenia. CNS Spectr. 2014; 19(Suppl 1): 3852; quiz 35–37, 53. doi: 10.1017/S1092852914000601
21. Correll, CU, Rubio, JM, Inczedy-Farkas, G, et al. Efficacy of 42 pharmacologic cotreatment strategies added to antipsychotic monotherapy in schizophrenia: systematic overview and quality appraisal of the meta-analytic evidence. JAMA Psychiatry. 2017; 74(7): 675684. doi: 10.1001/jamapsychiatry.2017.0624
22. Solmi, M, Murru, A, Pacchiarotti, I, et al. Safety, tolerability, and risks associated with first- and second-generation antipsychotics: a state-of-the-art clinical review. Ther Clin Risk Manag. 2017; 13: 757777. doi: 10.2147/TCRM.S117321
23. Correll, CU, Detraux, J, De Lepeleire, J, et al. Effects of antipsychotics, antidepressants and mood stabilizers on risk for physical diseases in people with schizophrenia, depression and bipolar disorder. World Psychiatry. 2015; 14(2): 119136. doi: 10.1002/wps.20204
24. Carbon, M, Kane, JM, Leucht, S, et al. Tardive dyskinesia risk with first- and second-generation antipsychotics in comparative randomized controlled trials: a meta-analysis. World Psychiatry. 2018; 17(3): 330340. doi: 10.1002/wps.20579
25. Carbon, M, Hsieh, C-H, Kane, JM, et al. Tardive dyskinesia prevalence in the period of second-generation antipsychotic use: a meta-analysis. J Clin Psychiatry. 2017; 78(3): e264e278. doi: 10.4088/JCP.16r10832
26. Vancampfort, D, Firth, J, Correll, CU, et al. The impact of pharmacological and non-pharmacological interventions to improve physical health outcomes in people with schizophrenia: a meta-review of meta-analyses of randomized controlled trials. World Psychiatry. 2019; 18(1): 5366. doi: 10.1002/wps.20614
27. Correll, CU, Solmi, M, Veronese, N, et al. Prevalence, incidence and mortality from cardiovascular disease in patients with pooled and specific severe mental illness: a large-scale meta-analysis of 3,211,768 patients and 113,383,368 controls. World Psychiatry. 2017; 16(2): 163180. doi: 10.1002/wps.20420
28. Vancampfort, D, Correll, CU, Galling, B, et al. Diabetes mellitus in people with schizophrenia, bipolar disorder and major depressive disorder: a systematic review and large scale meta-analysis. World Psychiatry. 2016; 15(2): 166174. doi: 10.1002/wps.20309
29. Vancampfort, D, Stubbs, B, Mitchell, AJ, et al. Risk of metabolic syndrome and its components in people with schizophrenia and related psychotic disorders, bipolar disorder and major depressive disorder: a systematic review and meta-analysis. World Psychiatry. 2015; 14(3): 339347. doi: 10.1002/wps.20252
30. Nielsen, J, Correll, CU, Manu, P, et al. Termination of clozapine treatment due to medical reasons: when is it warranted and how can it be avoided? J Clin Psychiatry. 2013; 74(6): 603613; quiz 613. doi: 10.4088/JCP.12r08064
31. Siskind, D, Siskind, V, Kisely, S. Clozapine response rates among people with treatment-resistant schizophrenia: data from a systematic review and meta-analysis. Can J Psychiatry Rev Can Psychiatry. 2017; 62(11): 772777. doi: 10.1177/0706743717718167
32. Howes, OD, McCutcheon, R, Agid, O, et al. Treatment-resistant schizophrenia: treatment response and resistance in psychosis (TRRIP) working group consensus guidelines on diagnosis and terminology. Am J Psychiatry. 2017; 174(3): 216229. doi: 10.1176/appi.ajp.2016.16050503
33. Yang, AC, Tsai, S-J. New targets for schizophrenia treatment beyond the dopamine hypothesis. Int J Mol Sci. 2017; 18(8): 1689. doi: 10.3390/ijms18081689
34. Garay, RP, Citrome, L, Samalin, L, et al. Therapeutic improvements expected in the near future for schizophrenia and schizoaffective disorder: an appraisal of phase III clinical trials of schizophrenia-targeted therapies as found in US and EU clinical trial registries. Expert Opin Pharmacother. 2016; 17(7): 921936. doi: 10.1517/14656566.2016.1149164
35. Köster, L-S, Carbon, M, Correll, CU. Emerging drugs for schizophrenia: an update. Expert Opin Emerg Drugs. 2014; 19(4): 511531. doi: 10.1517/14728214.2014.958148
36. Kane, JM, Kishimoto, T, Correll, CU. Non-adherence to medication in patients with psychotic disorders: epidemiology, contributing factors and management strategies. World Psychiatry. 2013; 12(3): 216226. doi: 10.1002/wps.20060
37. Kishimoto, T, Hagi, K, Nitta, M, et al. Effectiveness of long-acting injectable vs oral antipsychotics in patients with schizophrenia: a meta-analysis of prospective and retrospective cohort studies. Schizophr Bull. 2018; 44(3): 603619. doi: 10.1093/schbul/sbx090
38. Misawa, F, Kishimoto, T, Hagi, K, et al Safety and tolerability of long-acting injectable versus oral antipsychotics: a meta-analysis of randomized controlled studies comparing the same antipsychotics. Schizophr Res. 2016; 176(2–3): 220230. doi: 10.1016/j.schres.2016.07.018
39. Haddad, PM, Kishimoto, T, Correll, CU, et al. Ambiguous findings concerning potential advantages of depot antipsychotics: in search of clinical relevance. Curr Opin Psychiatry. 2015; 28(3): 216221. doi: 10.1097/YCO.0000000000000160
40. Kishimoto, T, Nitta, M, Borenstein, M, et al. Long-acting injectable versus oral antipsychotics in schizophrenia: a systematic review and meta-analysis of mirror-image studies. J Clin Psychiatry. 2013; 74(10): 957965. doi: 10.4088/JCP.13r08440
41. Kane, JM, Kishimoto, T, Correll, CU. Assessing the comparative effectiveness of long-acting injectable vs. oral antipsychotic medications in the prevention of relapse provides a case study in comparative effectiveness research in psychiatry. J Clin Epidemiol. 2013; 66(Suppl 8): S37S41. doi: 10.1016/j.jclinepi.2013.01.012
42. Kishimoto, T, Robenzadeh, A, Leucht, C, et al. Long-acting injectable vs oral antipsychotics for relapse prevention in schizophrenia: a meta-analysis of randomized trials. Schizophr Bull. 2014; 40(1): 192213. doi: 10.1093/schbul/sbs150
43. Ibeas Bih, C, Chen, T, Nunn, AVW, et al. Molecular targets of cannabidiol in neurological disorders. Neurother J Am Soc Exp Neurother. 2015; 12(4): 699730. doi: 10.1007/s13311-015-0377-3
44. White, CM. A review of human studies assessing Cannabidiol’s (CBD) therapeutic actions and potential. J Clin Pharmacol. 2019; 59: 923934. doi: 10.1002/jcph.1387
45. Leweke, FM, Mueller, JK, Lange, B, et al. Role of the endocannabinoid system in the pathophysiology of schizophrenia: implications for pharmacological intervention. CNS Drugs. 2018; 32(7): 605619. doi: 10.1007/s40263-018-0539-z
46. McGuire, P, Robson, P, Cubala, WJ, et al. Cannabidiol (CBD) as an adjunctive therapy in schizophrenia: a multicenter randomized controlled trial. Am J Psychiatry. 2018; 175(3): 225231. doi: 10.1176/appi.ajp.2017.17030325
47. Sokoloff, P, Le Foll, B. The dopamine D3 receptor, a quarter century later. Eur J Neurosci. 2017; 45(1): 219. doi: 10.1111/ejn.13390
48. Bitter, I, Lieberman, JA, Gaudoux, F, et al. Randomized, double-blind, placebo-controlled study of F17464, a preferential D3 antagonist, in the treatment of acute exacerbation of schizophrenia. Neuropsychopharmacology. 2019. doi: 10.1038/s41386-019-0355-2
49. Davis, RE, Correll, CU. ITI-007 in the treatment of schizophrenia: from novel pharmacology to clinical outcomes. Expert Rev Neurother. 2016; 16(6): 601614. doi: 10.1080/14737175.2016.1174577
50. Vanover, KE, Dimitrienko, A, Glass, SJ, et al. Lumateperone (ITI-007) for the treatment of schizophrenia: overview of placebo-controlled clinical trials and an open-label safety switching study. APA Conf Poster Present P5-178, San Francisco, USA, 2018.
51. Snyder, GL, Vanover, KE, Zhu, H, et al. Functional profile of a novel modulator of serotonin, dopamine, and glutamate neurotransmission. Psychopharmacology (Berl). 2015; 232(3): 605621. doi: 10.1007/s00213-014-3704-1
52. Lieberman, JA, Davis, RE, Correll, CU, et al. ITI-007 for the treatment of schizophrenia: a 4-week randomized, double-blind, controlled trial. Biol Psychiatry. 2016; 79(12): 952961. doi: 10.1016/j.biopsych.2015.08.026
53. Vanover, KE, O’Gorman, C, Glass, SJ, et al. Favorable clinical safety profile for lumateperone (ITI-007) switching from standard-of-care antipsychotic therapy in patients with schizophrenia. ACNP Conf 2017 Poster Present T189, California, USA.
54. Vanover, KE, Correll, CU, Weingart, M, et al. Long-term safety for lumateperone (ITI-007) in the treatment of schizophrenia. ACNP Conf 2018 Poster Present T184, Hollywood, USA.
55. Grauer, SM, Pulito, VL, Navarra, RL, et al. Phosphodiesterase 10A inhibitor activity in preclinical models of the positive, cognitive, and negative symptoms of schizophrenia. J Pharmacol Exp Ther. 2009; 331(2): 574590. doi: 10.1124/jpet.109.155994
56. Suzuki, K, Harada, A, Suzuki, H, et al. TAK-063, a PDE10A inhibitor with balanced activation of direct and indirect pathways, provides potent antipsychotic-like effects in multiple paradigms. Neuropsychopharmacology. 2016; 41(9): 22522262. doi: 10.1038/npp.2016.20
57. Macek, TA, McCue, M, Dong, X, et al. A phase 2, randomized, placebo-controlled study of the efficacy and safety of TAK-063 in subjects with an acute exacerbation of schizophrenia. Schizophr Res. 2019; 204:289294. doi: 10.1016/j.schres.2018.08.028
58. An Active-Controlled Early Phase Study of MK-8189 in Adults with Schizophrenia (MK-8189-005) – Study Results, Accessed March 28, 2019.
59. Crippa, JA, Hallak, JEC, Abílio, VC, et al. Cannabidiol and sodium nitroprusside: two novel neuromodulatory pharmacological interventions to treat and prevent psychosis. CNS Neurol Disord Drug Targets. 2015; 14(8): 970978.
60. Hallak, JEC, Maia-de-Oliveira, JP, Abrao, J, et al. Rapid improvement of acute schizophrenia symptoms after intravenous sodium nitroprusside: a randomized, double-blind, placebo-controlled trial. JAMA Psychiatry. 2013; 70(7): 668676. doi: 10.1001/jamapsychiatry.2013.1292
61. Wang, X, Zhao, J, Hu, Y, et al. Sodium nitroprusside treatment for psychotic symptoms and cognitive deficits of schizophrenia: a randomized, double-blind, placebo-controlled trial. Psychiatry Res. 2018; 269:271277. doi: 10.1016/j.psychres.2018.08.079
62. Stone, JM, Morrison, PD, Koychev, I, et al. The effect of sodium nitroprusside on psychotic symptoms and spatial working memory in patients with schizophrenia: a randomized, double-blind, placebo-controlled trial. Psychol Med. 2016; 46(16): 34433450. doi: 10.1017/S0033291716002245
63. Brown, HE, Freudenreich, O, Fan, X, et al. Efficacy and tolerability of adjunctive intravenous sodium nitroprusside treatment for outpatients with schizophrenia: a randomized clinical trial. JAMA Psychiatry. 2019; 76(7): 691699.
64. Maia-de-Oliveira, JP, Baker, GB, Dursun, SM, et al. Letter to the editor: sodium nitroprusside for schizophrenia: could methodological variables account for the different results obtained? Psychol Med. 2017; 47(5): 981982. doi: 10.1017/S003329171600307X
65. Schwartz, MD, Canales, JJ, Zucchi, R, et al. Trace amine-associated receptor 1: a multimodal therapeutic target for neuropsychiatric diseases. Expert Opin Ther Targets. 2018; 22(6): 513526. doi: 10.1080/14728222.2018.1480723
66. Revel, FG, Moreau, J-L, Pouzet, B, et al. A new perspective for schizophrenia: TAAR1 agonists reveal antipsychotic- and antidepressant-like activity, improve cognition and control body weight. Mol Psychiatry. 2013; 18(5): 543556. doi: 10.1038/mp.2012.57
67.A Study to Evaluate the Efficacy and Safety of SEP-363856 in Acutely Psychotic Adults with Schizophrenia – Full Text View, Accessed March 28, 2019.
68.A Study Assessing the Safety, Tolerability, and Pharmacokinetics of SEP-363856 in Male and Female Subjects with Schizophrenia – Full Text View, Accessed March 28, 2019.
69. Espinoza, S, Leo, D, Sotnikova, TD, et al. Biochemical and functional characterization of the trace amine-associated receptor 1 (TAAR1) agonist RO5263397. Front Pharmacol. 2018; 9: 645. doi: 10.3389/fphar.2018.00645
70. Fowler, S, Kletzl, H, Finel, M, et al. A UGT2B10 splicing polymorphism common in African populations may greatly increase drug exposure. J Pharmacol Exp Ther. 2015; 352(2): 358367. doi: 10.1124/jpet.114.220194
71. Poola, N, Sunkaraneni, S, Galluppi, G, et al. Pharmacokinetics, safety and tolerability of SEP-363856 in healthy adult male subjects and in adult patients with schizophrenia following oral administration. Poster Present. 2018; American College of Neuropsychopharmacology, Hollywood, FL, USA.
72. Umbricht, D, Alberati, D, Martin-Facklam, M, et al. Effect of bitopertin, a glycine reuptake inhibitor, on negative symptoms of schizophrenia: a randomized, double-blind, proof-of-concept study. JAMA Psychiatry. 2014; 71(6): 637646. doi: 10.1001/jamapsychiatry.2014.163
73. Bugarski-Kirola, D, Blaettler, T, Arango, C, et al. Bitopertin in negative symptoms of schizophrenia – results from the phase III FlashLyte and DayLyte studies. Biol Psychiatry. 2017; 82(1): 816. doi: 10.1016/j.biopsych.2016.11.014
74.Safety and Tolerability Study of Lu AF11167 after Repeated Dosing in Patients with Schizophrenia – Full Text View, Accessed March 28, 2019.
75. Meltzer, HY, Elkis, H, Vanover, K, et al. Pimavanserin, a selective serotonin (5-HT)2A-inverse agonist, enhances the efficacy and safety of risperidone, 2mg/day, but does not enhance efficacy of haloperidol, 2mg/day: comparison with reference dose risperidone, 6mg/day. Schizophr Res. 2012; 141(2–3): 144152. doi: 10.1016/j.schres.2012.07.029
76.Efficacy and Safety of Pimavanserin as Adjunctive Treatment for the Negative Symptoms of Schizophrenia (ADVANCE) – Full Text View, Accessed March 28, 2019.
77. Keefe, RSE, Harvey, PD, Khan, A, et al. Cognitive effects of MIN-101 in patients with schizophrenia and negative symptoms: results from a randomized controlled trial. J Clin Psychiatry. 2018; 79(3): 17m11753. doi: 10.4088/JCP.17m11753
78. Davidson, M, Saoud, J, Staner, C, et al. Efficacy and safety of MIN-101: a 12-week randomized, double-blind, placebo-controlled trial of a new drug in development for the treatment of negative symptoms in schizophrenia. Am J Psychiatry. 2017; 174(12): 11951202. doi: 10.1176/appi.ajp.2017.17010122
79. Staner, C, Davidson, M, Noel, N, et al. Results of an exploratory phase 2a study with MIN-101, a 5-HT2A/sigma-2 antagonist, for the treatment of schizophrenia. Present Sixth Bienn Schizophr Int Res Soc Conf Florence. 2016.
80.Study to Evaluate Efficacy and Safety of Roluperidone (MIN-101) in Adult Patients with Negative Symptoms of Schizophrenia – Full Text View, Accessed March 28, 2019.
81. Sacchi, S, Rosini, E, Pollegioni, L, et al. D-amino acid oxidase inhibitors as a novel class of drugs for schizophrenia therapy. Curr Pharm Des. 2013; 19(14): 24992511.
82.A Study to Evaluate Efficacy, Safety, Tolerability, and Pharmacokinetics of 3 Dose Levels of TAK-831 in Adjunctive Treatment of Adult Participants with Negative Symptoms of Schizophrenia – Full Text View, Accessed April 1, 2019.
83. Keefe, RSE, Meltzer, HA, Dgetluck, N, et al. Randomized, double-blind, placebo-controlled study of encenicline, an α7 nicotinic acetylcholine receptor agonist, as a treatment for cognitive impairment in schizophrenia. Neuropsychopharmacology. 2015; 40(13): 30533060. doi: 10.1038/npp.2015.176
84. Hashimoto, K, Malchow, B, Falkai, P, et al. Glutamate modulators as potential therapeutic drugs in schizophrenia and affective disorders. Eur Arch Psychiatry Clin Neurosci. 2013; 263(5): 367377. doi: 10.1007/s00406-013-0399-y
85. Moschetti, V, Desch, M, Goetz, S, et al. Safety, tolerability and pharmacokinetics of oral BI 425809, a glycine transporter 1 inhibitor, in healthy male volunteers: a partially randomised, single-blind, placebo-controlled, first-in-human study. Eur J Drug Metab Pharmacokinet. 2018; 43(2): 239249. doi: 10.1007/s13318-017-0440-z
86.Clinical Trial of BI 425809 Effect on Cognition and Functional Capacity in Schizophrenia – Full Text View, Accessed April 1, 2019.
87.This Study Tests Whether BI 425809 Together with Brain Training Using a Computer Improves Mental Functioning in Patients with Schizophrenia – Full Text View, Accessed April 1, 2019.
88. Boggs, DL, Surti, T, Gupta, A, et al. The effects of cannabidiol (CBD) on cognition and symptoms in outpatients with chronic schizophrenia a randomized placebo controlled trial. Psychopharmacology (Berl). 2018; 235(7): 19231932. doi: 10.1007/s00213-018-4885-9
89.Effect of Lu AF35700 in Patients with Treatment-Resistant Schizophrenia – Full Text View, Accessed March 28, 2019.
90.Efficacy of Lu AF35700 in Patients with Early-in-Disease or Late-in-Disease Treatment-Resistant Schizophrenia – Full Text View, Accessed March 28, 2019.
91.Lundbeck Updates on Clinical Phase III Study for Lu AF35700 in Treatment-Resistant Schizophrenia. H. Lundbeck A/S. Accessed March 11, 2019.
92.Efficacy and Safety of Adjunctive Pimavanserin for the Treatment of Schizophrenia (ENHANCE-1) – Full Text View, Accessed March 28, 2019.
93.ACADIA Pharmaceuticals Announces Top-line Results from Phase 3 ENHANCE Trial of Pimavanserin as Adjunctive Treatment for Patients with Schizophrenia, Accessed July 22, 2019.
94. Lin, C-H, Lin, C-H, Chang, Y-C, et al. Sodium benzoate, a D-amino acid oxidase inhibitor, added to clozapine for the treatment of schizophrenia: a randomized, double-blind, placebo-controlled trial. Biol Psychiatry. 2018; 84(6): 422432. doi: 10.1016/j.biopsych.2017.12.006
95. Lane, H-Y, Lin, C-H, Green, MF, et al. Add-on treatment of benzoate for schizophrenia: a randomized, double-blind, placebo-controlled trial of D-amino acid oxidase inhibitor. JAMA Psychiatry. 2013; 70(12): 12671275. doi: 10.1001/jamapsychiatry.2013.2159
96. Correll, CU, Citrome, L, Haddad, PM, et al. The use of long-acting injectable antipsychotics in schizophrenia: evaluating the evidence. J Clin Psychiatry. 2016; 77(Suppl 3): 124. doi: 10.4088/JCP.15032su1
97. Alkermes. FDA Approves ARISTADA INITIOTM for the Initiation of ARISTADA® for Schizophrenia. Press Release. July 2018.
98. Alkermes, Incl., Data on file. Clinical Study Report ALK9072-B102. Walth MA. 2017.
99. Hard, ML, Wehr, AY, Sadler, BM, et al. Population pharmacokinetic analysis and model-based simulations of aripiprazole for a 1-day initiation regimen for the long-acting antipsychotic aripiprazole lauroxil. Eur J Drug Metab Pharmacokinet. 2018; 43(4): 461469. doi: 10.1007/s13318-018-0488-4
100. Walling, D, Hard, ML, Wehr, A, et al. Aripiprazole lauroxil nanocrystal dispersion: a potential 1-day initiation regimen for long-acting aripiprazole lauroxil. Present Annu Meet Am Psychiatr Assoc. 2018.
101. Mathews, M, Gopal, S, Nuamah, I, et al. Clinical relevance of paliperidone palmitate 3-monthly in treating schizophrenia. Neuropsychiatr Dis Treat. 2019; 15: 13651379. doi: 10.2147/NDT.S197225
102. Indivior. PERSERIS (risperidone) for extended-release injectable suspension, for subcutaneous use. Prescr Inf. July 2018.
103. Indivior. FDA approves PERSERIS (risperidone) for extended-release injectable suspension for the treatment of schizophrenia in adults. Press Release. July 2018.
104. Citrome, L. Sustained-release risperidone via subcutaneous injection: a systematic review of RBP-7000 (PERSERISTM) for the treatment of schizophrenia. Clin Schizophr Relat Psychoses. 2018; 12(3): 130141. doi: 10.3371/CSRP.CI.101118
105. Patel, DB. A review on atrigel drug delivery system. J Global Pharma Technol. 2010; 2:8590.
106. Gomeni, R, Heidbreder, C, Fudala, PJ, et al. A model-based approach to characterize the population pharmacokinetics and the relationship between the pharmacokinetic and safety profiles of RBP-7000, a new, long-acting, sustained-released formulation of risperidone. J Clin Pharmacol. 2013; 53(10): 10101019. doi: 10.1002/jcph.141
107. Laffont, CM, Gomeni, R, Zheng, B, et al. Population pharmacokinetics and prediction of dopamine D2 receptor occupancy after multiple doses of RBP-7000, a new sustained-release formulation of risperidone, in schizophrenia patients on stable oral risperidone treatment. Clin Pharmacokinet. 2014; 53(6): 533543. doi: 10.1007/s40262-014-0132-7
108. Isitt, JJ, Nadipelli, VR, Kouassi, A, et al. Health-related quality of life in acute schizophrenia patients treated with RBP-7000 once monthly risperidone: an 8-week, randomized, double-blind, placebo-controlled, multicenter phase 3 study. Schizophr Res. 2016; 174(1–3): 126131. doi: 10.1016/j.schres.2016.03.020
109. Nasser, AF, Henderson, DC, Fava, M, et al. Efficacy, safety, and tolerability of RBP-7000 once-monthly risperidone for the treatment of acute schizophrenia: an 8-week, randomized, double-blind, placebo-controlled, multicenter phase 3 study. J Clin Psychopharmacol. 2016; 36(2): 130140. doi: 10.1097/JCP.0000000000000479
110. Ivaturi, V, Gopalakrishnan, M, Gobburu, JVS, et al. Exposure-response analysis after subcutaneous administration of RBP-7000, a once-a-month long-acting atrigel formulation of risperidone: E–R analysis of RBP-7000, a long acting risperidone formulation. Br J Clin Pharmacol. 2017; 83(7): 14761498. doi: 10.1111/bcp.13246
111. Graham, J, Fava, M, Newcomer, J, et al. Monthly extended-release risperidone injections (RBP-7000) in the treatment of schizophrenia: results from two phase III trials. Present Annu Meet Am Psychiatr Assoc. 2018.
112.Evaluate TV-46000 as Maintenance Treatment in Adult and Adolescent Patients with Schizophrenia – Full Text View, Accessed June 11, 2019.
113.A Study to Test if TV-46000 Is Safe for Maintenance Treatment of Schizophrenia – Full Text View, Accessed June 11, 2019.
114.Laboratorios Farmacéuticos ROVI - DORIA Phase III trial hits primary endpoint • Edison. Accessed March 28, 2019.
115.Study to Evaluate the Efficacy and Safety of Risperidone ISM® in Patients with Acute Schizophrenia – No Study Results Posted, Accessed April 2, 2019.
116. Solmi, M, Pigato, G, Kane, JM, et al. Treatment of tardive dyskinesia with VMAT-2 inhibitors: a systematic review and meta-analysis of randomized controlled trials. Drug Des Devel Ther. 2018; 12: 12151238. doi: 10.2147/DDDT.S133205
117. Correll, CU, Manu, P, Olshanskiy, V, et al. Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents. JAMA J Am Med Assoc. 2009; 302(16): 17651773. doi: 10.1001/jama.2009.1549
118. De Hert, M, Detraux, J, van Winkel, R, et al. Metabolic and cardiovascular adverse effects associated with antipsychotic drugs. Nat Rev Endocrinol. 2011; 8(2): 114126. doi: 10.1038/nrendo.2011.156
119. Correll, CU, Lencz, T, Malhotra, AK. Antipsychotic drugs and obesity. Trends Mol Med. 2011; 17(2): 97107. doi: 10.1016/j.molmed.2010.10.010
120. Leucht, S, Cipriani, A, Spineli, L, et al. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet Lond Engl. 2013; 382(9896): 951962. doi: 10.1016/S0140-6736(13)60733-3
121. Lieberman, JA, Stroup, TS, McEvoy, JP, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med. 2005; 353(12): 12091223. doi: 10.1056/NEJMoa051688
122. Wentland, MP, Lou, R, Lu, Q, et al. Syntheses of novel high affinity ligands for opioid receptors. Bioorg Med Chem Lett. 2009; 19(8): 22892294. doi: 10.1016/j.bmcl.2009.02.078
123. Silverman, BL, Martin, W, Memisoglu, A, et al. A randomized, double-blind, placebo-controlled proof of concept study to evaluate samidorphan in the prevention of olanzapine-induced weight gain in healthy volunteers. Schizophr Res. 2018; 195: 245251. doi: 10.1016/j.schres.2017.10.014
124. Sun, L, McDonnell, D, von Moltke, L. Pharmacokinetics and short-term safety of ALKS 3831, a fixed-dose combination of olanzapine and samidorphan, in adult subjects with schizophrenia. Clin Ther. 2018; 40(11): 18451854.e2. doi: 10.1016/j.clinthera.2018.09.002
125. Martin, WF, Correll, CU, Weiden, PJ, et al. Mitigation of olanzapine-induced weight gain with samidorphan, an opioid antagonist: a randomized double-blind phase 2 study in patients with schizophrenia. Am J Psychiatry. 2019; 176: 457467. doi: 10.1176/appi.ajp.2018.18030280
126. Correll, C, Kahn, R, Silverman, B, et al. Combination of olanzapine and samidorphan limits the weight gain observed with olanzapine alone: results from the phase 3 ENLIGHTEN-2 schizophrenia study. Presented at the Schizophrenia International Research Society (SIRS) meeting; April 10, 2019; Orlando, Florida, USA.
127.Alkermes Announces Positive Topline Results from ENLIGHTEN-2 Phase 3 Study of ALKS 3831 in Patients with Schizophrenia. Accessed March 28, 2019.
128. Potkin, SG, Kunovac, J, Silverman, BL, et al. 26 A phase 3 study to determine the antipsychotic efficacy and safety of ALKS 3831 in adult patients with acute exacerbation of schizophrenia. CNS Spectr. 2019; 24(1): 187188. doi: 10.1017/S1092852919000208
129.Alkermes Announces Positive Topline Results from ENLIGHTEN-2 Phase 3 Study of ALKS 3831 in Patients with Schizophrenia. Accessed March 28, 2019.
130. Correll, CU, What are we looking for in new antipsychotics? J Clin Psychiatry. 2011; 72(Suppl 1): 913. doi: 10.4088/JCP.10075su1.02
131. Correll, CU, Vanover, KE, Glass, SJ, et al. Favorable clinical safety profile for lumateperone 8ITI-007 – switching from standard-of-care (SOC) antipsychotic therapy in patients with schizophrenia. CINP Conf 2018 Poster Present PM161, Vienna Austria.


Keeping up with the therapeutic advances in schizophrenia: a review of novel and emerging pharmacological entities

  • Amanda Krogmann (a1), Luisa Peters (a1), Laura von Hardenberg (a1), Katja Bödeker (a1), Viktor B. Nöhles (a1) and Christoph U. Correll (a1) (a2) (a3)...


Full text views

Total number of HTML views: 0
Total number of PDF views: 0 *
Loading metrics...

Abstract views

Total abstract views: 0 *
Loading metrics...

* Views captured on Cambridge Core between <date>. This data will be updated every 24 hours.

Usage data cannot currently be displayed